A higher dose of fulvestrant is well tolerated and more active than the standard, lower dose in postmenopausal patients with advanced breast cancer. "We believe that, based on the results of this study, treatment and practice should change; patients should receive the 500 mg dose," said Angelo Di Leo, M.D., Ph.D., director of the Department of Oncology at the Hospital of Prato, Italy. Official San Antonio Breast Cancer Symposium press conference.